Information Provided By:
Fly News Breaks for February 10, 2020
Feb 10, 2020 | 07:45 EDT
Cowen analyst Chris Shibutani initiated coverage of Ardelyx with an Outperform rating. The analyst expects tenapanor, which was approved for irritable bowel syndrome with constipation in September, to be approve for hyperphosphatemia in dialysis patients by mid-2021. He sees the opportunity as de-risked and underappreciated and a key catalst in the next 18 months.
News For ARDX From the Last 2 Days
There are no results for your query ARDX